VYNE Therapeutics (VYNE) EBITDA Margin (2017 - 2026)
VYNE Therapeutics (VYNE) posted EBITDA Margin of 4437.21% for Q1 2026, up 41.17% on a QoQ basis from 7542.0% in Q2 2025, and up 16129.0% year-over-year from N/an in Q1 2025.
VYNE Therapeutics (VYNE) EBITDA Margin (2017 - 2026) Analysis & Trends
VYNE Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 4437.21% for Q1 2026.
- Quarterly EBITDA Margin rose 16129.0% year-over-year to 4437.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7105.54% (up 44495.0% YoY) and the FY2025 annual result came in at 5219.12%, up 350828.0% from the prior year.
- EBITDA Margin was 4437.21% for Q1 2026 at VYNE Therapeutics, up from 7542.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 4437.21% in Q1 2026 and bottomed at 27531.03% in Q4 2022.
- A 5-year average of 8709.53% and a median of 6576.98% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 2429074 bps — and 2023, when it soared 1854156 bps.
- VYNE Therapeutics' EBITDA Margin stood at 27531.03% in 2022, then jumped by 67 bps to 8989.47% in 2023, then tumbled by 71 bps to 15385.54% in 2024, then soared by 51 bps to 7542.0% in 2025, then jumped by 41 bps to 4437.21% in 2026.
- Business Quant data shows VYNE's EBITDA Margin at 4437.21% in Q1 2026, 7542.0% in Q2 2025, and 4598.5% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -4,437.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,437.21% |
| Jun 30, 2025 | -7,542.00% |
| Mar 31, 2025 | -4,598.50% |
| Dec 31, 2024 | -15,385.54% |
| Sep 30, 2024 | -10,819.01% |
| Jun 30, 2024 | -5,250.51% |
| Mar 31, 2024 | -7,380.00% |
| Dec 31, 2023 | -8,989.47% |
| Sep 30, 2023 | -5,468.42% |
| Jun 30, 2023 | -10,318.00% |
| Mar 31, 2023 | -5,875.00% |
| Dec 31, 2022 | -27,531.03% |
| Sep 30, 2022 | -5,588.62% |
| Jun 30, 2022 | -6,576.98% |
| Mar 31, 2022 | -4,882.58% |
| Dec 31, 2021 | -3,240.29% |
| Sep 30, 2021 | -8,095.49% |
| Jun 30, 2021 | -3,234.58% |
| Mar 31, 2021 | -4,242.17% |
| Dec 31, 2020 | -513.04% |